---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016922"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:53:38.327218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q1 net loss $5.2M; progresses COVID-19/flu trials; raises $4M

## Summary
- Net loss of $5.2M ($0.64/share) vs $4.2M ($0.52) in Q1 2022; R&D expense $3.9M (up from $2.9M).
- Cash of $34.0M at March 31, 2023; working capital $33.8M; 8.1M shares outstanding.
- Raised $4M via private placement from directors Dr. Phillip Frost and Fred Hassan; Hassan joined board.
- Submitted application for Phase 1 trial of COVID-19 oral protease inhibitor CDI-988 in Australia.
- Expects to start Phase 2a human challenge study for influenza A candidate CC-42344 in H2 2023.

## SEC filing metadata
- accession: 0001493152-23-016922
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/0001493152-23-016922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016922
- JSON: https://secwatch.observer/filing/0001493152-23-016922.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016922.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for three months ended March 31, 2023.
  - Period: three months ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/0001493152-23-016922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.